increment management discuss
increment follow earn releas conf call chanc
catch manag offer follow increment takeaway
compani continu road improv medicaid
evidenc lack neg call-out topic result
may slightli challeng hit membership guidanc
like make better posit growth addit
breakdown management modest revenu guid reduct slightli
bn initi guid follow transit script
optumrx estimate mn transit script worth bn voluntari exit
iowa medicaid program bn partial off-set addit revenu
dmg acquisit bn relat pbm contract ci
mn script optumrx worth bn annual rev mn script
transit expect remain mn script bn transit
despit larg revenu believ well understood investor ep
impact relat ci immateri given margin busi
separ voluntarili exit iowa medicaid bn annual
state sourc financi pressur sinc revenu loss also like
minim earn impact could actual addit accord management
regard membership low-end guidanc rang impli
addit live appear high hurdl clear without
acquisit management comment seem confirm notion took
conserv multi-year approach bid rel peer help
explain unh market-lik retail growth vs market growth
importantli conserv strategi help compani maintain stabl
benefit potenti set stage acceler growth page
addit detail increas ep reflect today result dmg
close see figur pt still base price-to-earnings ep estimate
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight price target
group base price-to-earnings ep
believ deserv premium valuat
diversifi peer due faster earn growth
stem optum medicar
upsid case reflect favor medic
cost trend outlook increas share gain
uhc optum
downsid case reflect risk associ
increas cost trend agress commerci price
pbm regulatori risk
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
dmg potenti ep contribut estim ep contribut
may challeng hit membership guidanc
unh membership total mn live impli live need
hit year-end target mn live last year compani ad live
back half year includ acquisit thu without similarli
size acquisit year compani could risk fall short
howev even miss member major concern ep
investor sentiment view unh membership like pressur
somewhat signific growth aetna year like
reflect gener benefit two competitor hif schedul
resum like better competit posit maintain stabl benefit
may help acceler growth next year medicar membership
trend pleas see latest medicar enrol report look juli data
high annual assum ebit margin tax share count -end ad live acquir barclay
 annual incom statement compani compani yr/yr compani medic loss product product profit total incom intang amort pre-tax rate minor interest net incom exclud check ep fulli dilut share barclay
 earn membership unit healthcar part mn employ metricscar bnoptum bncare segmentoptumhealth consum mnoptuminsight bnoptumrx adj mngroup target oper incom loss bpsoper bpsdividend paid share repurchas wtd averag dilut s/o share barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
